ARTICLE | Company News
Oxford BioMedica, GlaxoSmithKline deal
January 6, 2014 8:00 AM UTC
On Dec. 18, 2013, Oxford BioMedica granted GlaxoSmithKline an option to a non-exclusive license to develop and commercialize up to six products to treat rare Orphan diseases based on Oxford's LentiVec...